A vaccine that stops all four strains and works for everyone
For more than a decade, Brazil's Butantan Institute has been pursuing a vaccine capable of protecting anyone — the previously infected and the never-exposed alike — against all four strains of dengue. In December 2022, that work reached a quiet but significant threshold: preliminary Phase III trial data, drawn from 17,000 volunteers, was delivered to the national health regulator Anvisa. The full submission is not expected until mid-2024, but the urgency behind it is already written in the numbers — 978 Brazilians died from dengue in 2022, the highest toll in seven years.
- Dengue killed 978 Brazilians in 2022 — the deadliest year since 2015 — and the trend had reversed sharply after years of decline, signaling a disease accelerating beyond current defenses.
- The only approved dengue vaccine in Brazil, Sanofi's Dengvaxia, is restricted to those already exposed to the virus and sold exclusively through private clinics, leaving the broader public without accessible protection.
- Butantan's candidate must clear a formidable scientific bar: it has to work against all four dengue strains and perform safely in both previously infected and dengue-naive individuals — a challenge that has stretched development past a decade.
- Early results offered a promising signal — 100% antibody production across trial participants — but Phase III must now confirm whether those antibodies translate into real-world protection.
- With preliminary data now in Anvisa's hands and a full regulatory submission targeted for mid-2024, the path toward a publicly distributed vaccine is advancing, though the finish line remains more than a year away.
On December 14th, 2022, researchers from Brazil's Butantan Institute carried preliminary trial data into the offices of Anvisa, the country's health regulator. It was a milestone earned over more than a decade of laboratory work — but not yet a conclusion. The complete regulatory submission, officials acknowledged, would not arrive until mid-2024.
The vaccine is currently in Phase III trials, the stage that tests whether a drug works in real people at scale. Seventeen thousand volunteers — adults, teenagers, and children — are enrolled. Earlier results had been encouraging: every participant who received the vaccine produced antibodies. The critical question now is whether those antibodies actually prevent illness.
Dengue makes vaccination unusually difficult. The virus exists in four distinct strains, and a viable vaccine must defend against all of them. It must also work differently depending on the recipient — those who have previously had dengue respond immunologically in ways that differ from those who have never been infected. Any effective vaccine has to account for both populations. That complexity explains why the work has taken so long.
Brazil already has a dengue vaccine: Sanofi's Dengvaxia, approved in 2015. But it can only be administered to people with prior dengue exposure, and it is sold exclusively through private clinics — out of reach for much of the population.
The cost of that gap became starkly visible in 2022. After years of fluctuating death tolls — 840 in 2019, then a pandemic-era dip to 244 in 2021 — dengue surged back with force, claiming 978 lives. It was the highest annual toll since 2015. The case for a publicly distributed vaccine, one that works for anyone regardless of prior infection, had never been more urgent.
On Wednesday, December 14th, Brazil's Butantan Institute walked preliminary data on its dengue vaccine into the offices of Anvisa, the country's health regulator. It was a milestone of sorts—the culmination of more than a decade of laboratory work—but not yet the finish line. The full regulatory submission, officials said, would not arrive until the middle of 2024.
The vaccine is currently in Phase III clinical trials, the stage where scientists measure whether a drug actually works in real people and whether it is safe to use. Seventeen thousand volunteers of various ages, including children, are enrolled in the study. Earlier results, published in March of that year, had shown something encouraging: the vaccine triggered antibody production in every single person who received it. Now the researchers needed to know whether those antibodies would actually protect people from getting sick.
Dengue is a stubborn disease to vaccinate against. The virus comes in four distinct strains—DENV-1, DENV-2, DENV-3, and DENV-4—and a useful vaccine must guard against all of them. There is another wrinkle: the vaccine needs to work differently depending on who receives it. Some people have already had dengue and recovered; others have never been infected. The immune system responds differently in each case, and the vaccine has to account for both scenarios. This is why the work has taken so long.
A dengue vaccine already exists in Brazil. Sanofi's Dengvaxia arrived in 2015 and protects against all four strains. But it comes with a significant limitation: it can only be given to people who have already been exposed to the virus. The Brazilian Society of Immunization says it is approved for children nine and older, teenagers, and adults up to forty-five. It is sold only in private clinics and hospitals, making it inaccessible to much of the population.
The urgency of finding a public alternative became impossible to ignore in 2022. Brazil recorded 978 deaths from dengue that year, the highest annual toll since 2015, when 986 people died. The numbers had been climbing steadily. In 2019, before the pandemic, 840 people died. By 2020, that had fallen to 574, and in 2021 to 244. But 2022 reversed the trend sharply. The disease was spreading faster, hitting harder, and killing more people than it had in years. A vaccine that could be distributed through the public health system—one that worked for anyone, regardless of prior infection—would be a tool the country desperately needed.
Citas Notables
The vaccine must protect against four dengue strains while working for both previously infected and naive populations— Butantan Institute research findings
La Conversación del Hearth Otra perspectiva de la historia
Why has this vaccine taken so long? Dengue has been around for centuries.
Because dengue isn't one disease—it's four. You need one vaccine that stops all four strains, and that's genuinely hard. But there's another layer: the vaccine has to work for someone who's never had dengue and also for someone who already recovered from it. Those are almost two different problems.
So the Sanofi vaccine doesn't solve this?
It solves part of it. Dengvaxia works well, but only if you've already been infected. It can't be given to someone who's never had dengue. That's a huge limitation in a country where you want to vaccinate everyone.
Why does prior infection matter so much?
Your immune system remembers. If you've had dengue before, your body recognizes the virus differently the second time around. A vaccine has to account for that memory. If you've never had it, your immune system is starting from zero. One vaccine that handles both situations is much harder to design.
The trial showed 100% antibody production. Isn't that a sign it works?
It's a very good sign. Antibodies are what you want to see. But Phase III is about whether those antibodies actually protect people in the real world. You can have all the antibodies in the world and still get sick if they're not the right kind or not strong enough.
Why did 2022 see so many deaths?
The virus was spreading faster than it had in years. You had 978 deaths—more than any year since 2015. That's what makes this work urgent. Right now, if you're poor, you can't access Dengvaxia. A public vaccine would change that.